drugset / Trial / NCT01170143
Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the efficacy in terms of the pathological complete response rate (pCR) to preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH)
Timeline
- Start
- 2009-08
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Trastuzumab | Monoclonal antibody | 2 mg/kg | — |
| Comparator | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |